Moreover, compared with the individuals who had MAVS methylation levels less than or equal to 21.16% without hrHPV infection, the risk of CPL was 4.33-fold higher in those who were hrHPV-positive and had MAVS methylation levels above 21.16% (ORa= 4.33, 95% CI = 1.78-10.52, Pa = 0.001) (Figure 3B). This evidence concerns the gene MAVS and congenital pulmonary lymphangiectasia.